To evaluate how genetic variations contribute to these characteristics, or phenotypes, the researchers evaluated genotypes from the 100K Affymetrix GeneChip Human Mapping Set using DNA from 1,345 FHS participants in two generations. This genotyping technology tests subjects DNA at 100,000 sites along the genome where people are known to commonly differ. Researchers then looked for association between the genotypes and 987 clinical phenotype measures, collected by the FHS over 59 years of follow up, including cardiovascular risk factors and biomarkers; cardiovascular disease; cancer; longevity and aging; and traits in the areas of lung function, sleep, neurology, and renal and endocrine function.
It is our hope that the results from the genome-wide association study will lead to a deeper understanding of the role of common genetic variation in the development of cardiovascular disease and its risk factors, said Philip A. Wolf, MD, principal investigator of this study and a professor of neurology, research professor of medicine (epidemiology and preventive medicine) at BUSM. Although these results should be considered hypothesis generating and need to be replicated, these papers clearly provide proof of genome-wide associations, he added.
According to the researchers, because NCBIs dbGaP Web site permits investigators to review patterns of statistical significance within the unfiltered genetic association tests across the entire human genome, researchers around the world will be able to rapidly access and potentially replicate or refute findings from the FHS 100K study or d
|Contact: Gina DiGravio|